New non-solvated crystalline form of fluorinated estratriene-diol derivative, useful as antiestrogen e.g. for treating breast or endometrial cancer, chemotherapy-induced alopecia, endometriosis or anovulatory infertility

A new non-solvated crystalline form (A) of 11 beta -fluoro-7 alpha -(5-(N-methyl-N-(7,7,8,8,9,9,10,10,10-nonafluorodecyl)-amino)-pentyl)-estra-1,3,5(10)-triene-3,17 beta -diol (I) has melting point 141 \! 2 deg C (by differential thermographic analysis). A new non-solvated crystalline form (A) of 11 beta -fluoro-7 alpha -(5-(N-methyl-N-(7,7,8,8,9,9,10,10,10-nonafluorodecyl)-amino)-pentyl)-estra-1,3,5(10)-triene-3,17 beta -diol of formula (I) has melting point 141 \! 2 deg C (by differential thermographic analysis). Independent claims are included for the preparation (crystallization) of (A).